XIGEN CLOSES ITS SERIES A FINANCING ROUND WITH CHF 26M (21M USD)

Xigen S.A., a Swiss biotechnology company engaged in research and development of intracellular peptide therapeutics for the treatment of stroke, myocardial infarction and cancer, announced today the successful conclusion of its Swiss Francs 26m (21m USD) Series A financing round with Tilocor Life Sciences, Venture Incubator (VI) and Initiative Capital (IC) as investors.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050906005468&newsLang=en)